News & Events
- Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021
- Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer
- Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium
- Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
- Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology
- Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
- Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
- Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
- Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
- Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis
- Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020
- Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer
- Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting
- Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020
- Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients